EVE Health Group (ASX:EVE) Research & Development: A$0.12 Mil (TTM As of Dec. 2025)


What is EVE Health Group Research & Development?

EVE Health Group ASX:EVE -2.44% Research & Development is A$0.12 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. EVE Health Group's Research & Development for the six months ended in Dec. 2025 was A$0.12 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.12 Mil.

EVE Health Group  (ASX:EVE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

EVE Health Group Research & Development Related Terms

EVE Health Group Research & Development Historical Data

* Premium members only.

The historical data trend for EVE Health Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EVE Health Group Research & Development Chart

EVE Health Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EVE Health Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.12

EVE Health Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.12 Mil mean?
EVE Health Group (ASX:EVE) has a Research & Development of A$0.12 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on EVE Health Group and its competitors.
Is EVE Health Group's Research & Development too high?
EVE Health Group's current Research & Development is A$0.12 Mil.
How does EVE Health Group's Research & Development compare to KHC and GIS?
EVE Health Group's Research & Development of A$0.12 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on EVE Health Group and its competitors. EVE Health Group's current Research & Development is A$0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EVE Health Group stock overvalued right now?
Based on GuruFocus' analysis, EVE Health Group (ASX:EVE) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.02 — trading 100% above its estimated fair value. The current Research & Development is A$0.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For EVE Health Group (ASX:EVE), the current Research & Development is A$0.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EVE Health Group Business Description

Address 245 Churchill Avenue, Suite 1, Subiaco, WA, AUS, 6008
EVE Health Group Ltd is an integrated Health, Nutrition, and Wellness investment company. The company operates in two reporting segments, namely Meluka (branded wellness consumer products) and Nextract.